🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. VX-147 film-coated tablet, VX-147, Coated Placebo Tablet

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Proteinuric Kidney Disease (AMKD)

    phase 3 small molecule active

    1 trial

  2. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 fixed-dose combination granules, Kalydeco 75 mg granules in sachet, Kalydeco 75 mg film-coated tablets, VX-770 75mg, VX-770 granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kaftrio 75 mg/50 mg/100 mg film-coated tablets, Kalydeco 150 mg film-coated tablets

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  3. VX-880

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetes Mellitus, Type 1

    phase 3 mab active

    1 trial

  4. VX-880 solution for infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus with Impaired Hypoglycemic Awareness and Severe Hypoglycemia

    phase 3 small molecule active

    1 trial

  5. Vectibix 20 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  6. Vedolizumab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    9 trials

  7. Vedolizumab

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    5 trials

  8. Vedolizumab

    Takeda

    Pouchitis

    phase 3 small molecule active

    1 trial

  9. Vedolizumab

    Takeda

    Primary Sclerosing Cholangitis

    phase 3 small molecule terminated

    1 trial

  10. Vedolizumab 300 mg IV

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  11. Vedolizumab IV

    Takeda

    Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  12. Vedolizumab IV

    Takeda

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  13. Vedolizumab IV

    Takeda

    Ulcerative Colitis

    phase 3 small molecule active

    4 trials

  14. Vedolizumab IV

    Takeda

    Crohn's Disease

    phase 3 small molecule active

    2 trials

  15. Vedolizumab Placebo

    Takeda

    Hematopoietic Stem Cells

    phase 3 small molecule completed

    1 trial

  16. Vedolizumab SC

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  17. Vedolizumab SC

    Takeda

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  18. Vedolizumab SC 108 mg

    Takeda

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  19. Venclexta, Venclyxto, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Venclexta, Venclyxto, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Venclexta, Venclyxto, Fludarabin Ebewe 25 mg/ml injektio-/infuusiokonsentraatti, liuosta varten, Fludarabin Sandoz 25 mg/ml injekčný alebo infúzny koncentrát, MabThera 500 mg concentrate for solution for infusion, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, Bendamustin cell pharm® 2,5

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  20. Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, BGB-11417, MabThera 100 mg concentrate for solution for infusion, BGB-11417, BGB-11417, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, MabThera 500 mg concentrate for solution for infusion, Venclyxto 50 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  21. Venclyxto 100 mg film-coated tablets, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, BGB-16673, BGB-16673, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Zydelig 150 mg film-coated tablets, Zydelig 100 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphotic leukemia and Small Lymphocytic lymphoma

    phase 3 small molecule active

    1 trial

  22. Venclyxto 100 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, Zanubrutinib, Venclyxto 50 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  23. Venetoclax

    AbbVie

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  24. Venetoclax in combination with fludarabine and melphalan

    The First People's Hospital of Lianyungang

    Venentoclax

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources